Polycystic Ovary Syndrome in Adolescents

Endocrinology and Metabolism Clinics of North America

Volumn 45, Issue 2, 2016, Pages 329-344

  Witchel, Selma Feldman ^a   Roumimper, Hailey ^b   Oberfield, Sharon ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b Department of Medicine   (United States)

Author keywords

Adolescent; Hyperandrogenism; Irregular menses; Metabolic syndrome; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; CONTRACEPTIVE AGENT; METFORMIN; MUELLERIAN INHIBITING FACTOR;

ADOLESCENT; CONSENSUS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; FEMALE; GENETICS; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MENSTRUATION DISORDER; METABOLIC DISORDER; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PUBERTY; REVIEW; SYMPTOMATOLOGY; WEIGHT REDUCTION; COMPLICATION; OBESITY; OLIGOMENORRHEA; PATHOPHYSIOLOGY;

ADOLESCENT; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; OBESITY; OLIGOMENORRHEA; POLYCYSTIC OVARY SYNDROME;

EID: 84961878429     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2016.01.004     Document Type: Review

References (93)

1. 1 Zawadzki, J., Dunaif, A., Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Dunaif, A., Givens, H.R., Haseltine, F.P., et al. (eds.) Polycystic ovary syndrome, 1992, Blackwell Scientific, Boston (MA), 377–384.
2. 2 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:1 (2004), 19–25.
3. 3 March, W.A., Moore, V.M., Wilson, K.J., et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25:2 (2010), 544–551.
4. 4 Yildiz, B.O., Bozdag, G., Yapici, Z., et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 27:10 (2012), 3067–3073.
5. 5 Azziz, R., Carmina, E., Dewailly, D., et al., Androgen Excess Society, Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guidelines. J Clin Endocrinol Metab 91:11 (2006), 4237–4245.
6. 6 National Institutes of Health, Evidence-based methodology workshop on polycystic ovary syndrome: executive summary. 2012, National Institutes of Health, Bethesda, Maryland.
7. 7 Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98:12 (2013), 4565–4592.
8. 8 Diamanti-Kandarakis, E., Dunaif, A., Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33:6 (2012), 981–1030.
9. 9 Polotsky, A.J., Allshouse, A.A., Crawford, S.L., et al. Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. J Clin Endocrinol Metab 99:6 (2014), 2120–2127.
10. 10 Randeva, H.S., Tan, B.K., Weickert, M.O., et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 33:5 (2012), 812–841.
11. 11 Dumesic, D.A., Oberfield, S.E., Stener-Victorin, E., et al. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev 36 (2015), 487–525.
12. 12 Apter, D., Butzer, T., Lauglin, G.A., et al. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab 79:1 (1994), 119–125.
13. 13 Ibáñez, L., Ong, K.K., López-Bermejo, A., et al. Hyperinsulinaemic androgen excess in adolescent girls. Nat Rev Endocrinol 10:8 (2014), 499–508.
14. 14 Carmina, E., Oberfield, S.E., Lobo, R.A., The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 203:3 (2010), e1–e5.
15. 15 Hardy, T.S., Norman, R.J., Diagnosis of adolescent polycystic ovary syndrome. Steroids 78:8 (2013), 751–754.
16. 16 Rosenfeld, R.L., The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 136:6 (2015), 1154–1165.
17. 17 Sultan, C., Paris, F., Clinical expression of polycystic ovary syndrome in adolescent girls. Fertil Steril, 86(Suppl 1), 2006, S6.
18. 18 Fauser, B.C., Tarlatzis, B.C., Rebar, R.W., et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97:Suppl 1 (2012), 28–38.e25.
19. 19 Dokras, A., Witchel, S.F., Are young adult women with polycystic ovary syndrome slipping through the healthcare cracks?. J Clin Endocrinol Metab 99 (2014), 1583–1585.
20. 20 Witchel, S.F., Oberfield, S.E., Rosenfeld, R.L., et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr, 83(6), 2015.
21. 21 Legro, R.S., Driscoll, D., Strauss, J.F. 3rd, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 95:25 (1998), 14956–14960.
22. 22 Vink, J.M., Sadrzadeh, S., Lambalk, C.B., et al. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 91:6 (2006), 2100–2104.
23. 23 Barber, T.M., Franks, S., Genetics of polycystic ovary syndrome. Front Horm Res 40 (2013), 28–39.
24. 24 Chen, Z.J., Zhao, H., He, L., et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 43:1 (2011), 55–59.
25. 25 Shi, Y., Zhao, H., Shi, Y., et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 44:9 (2012), 1020–1025.
26. 26 Hayes, M.G., Urbanek, M., Ehrmann, D.A., et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun, 6, 2015, 7502.
27. 27 Day, F.R., Hinds, D.A., Tung, J.Y., et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun, 6, 2015, 8464.
28. 28 McAllister, J.M., Modi, B., Miller, B.A., et al. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci U S A 111:15 (2014), E1519–E1527.
29. 29 Nelson, V.L., Legro, R.S., Strauss, J.F., et al. Augmented Androgen Production is a Stable Steroidogenic Phenotype of Propagated Theca Cells from Polycystic Ovaries. Mol Endocrinol 13 (1999), 946–957.
30. 30 Coviello, A.D., Legro, R.S., Dunaif, A., Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91:2 (2006), 492–497.
31. 31 Fruzzetti, F., Perini, D., Lazzarini, V., et al. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril 92:2 (2009), 626–634.
32. 32 Hickey, M., Doherty, D.A., Atkinson, H., et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod 26:6 (2011), 1469–1477.
33. 33 Lucky, A.W., Biro, F.M., Simbartl, L.A., et al. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. [see comments] J Pediatr 130:1 (1997), 30–39.
34. 34 Roe, A.H., Prochaska, E., Smith, M., et al. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J Pediatr 162:5 (2013), 937–941.
35. 35 Yildiz, B.O., Bolour, S., Woods, K., et al. Visually scoring hirsutism. Hum Reprod Update 16:1 (2010), 51–64.
36. 36 Martin, K.A., Chang, R.J., Ehrmann, D.A., et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:4 (2008), 1105–1120.
37. 37 Merino, P.M., Codner, E., Cassorla, F., A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence. Arq Bras Endocrinol Metabol 55:8 (2011), 590–598.
38. 38 Biro, F.M., Emans, S.J., Whither PCOS? The challenges of establishing hyperandrogenism in adolescent girls. J Adolesc Health 43:2 (2008), 103–105.
39. 39 Rosner, W., Auchus, R.J., Azziz, R., et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: and Endocrine Society position statement. J Clin Endocrinol Metab 92:2 (2007), 405–413.
40. 40 Legro, R.S., Schlaff, W.D., Diamond, M.P., et al. Reproductive medicine Network. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab 95:12 (2010), 5305–5313.
41. 41 Venturoli, S., Procu, E., Fabbri, R., et al. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. J Clin Endocrinol Metab 74:4 (1992), 836–841.
42. 42 Rosenfeld, R.L., Ehrmann, D.A., Littlejohn, E.E., Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab 100:4 (2015), 1537–1543.
43. 43 American Academy of Pediatrics Committee on Adolescence, American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz, A., Laufer, M.R., Breech, L.L., Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 118:5 (2006), 2245–2250.
44. 44 Apter, D., Vihko, R., Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinool Metab 57:1 (1983), 82–86.
45. 45 van Hooff, M.H., Voorhorst, F.J., Kaptein, M.B., et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Repod 19:2 (2004), 383–392.
46. 46 Flug, D., Largo, R.H., Prader, A., Menstrual patterns in adolescent Swiss girls: a longitudinal study. Ann Hum Biol 11:6 (1984), 495–508.
47. 47 Rosenfeld, R.L., The polycystic ovary morphology-polycystic ovary syndrome spectrum. J Pediatr Adolesc Gynecol 28:6 (2015), 412–419.
48. 48 Franks, S., Stark, J., Hardy, K., Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 14:4 (2008), 367–378.
49. 49 Chang, R.J., Cook-Andersen, H., Disordered follicle development. Mol Cell Endocrinol 373:1–2 (2013), 51–60.
50. 50 Polson, D.W., Adams, J., Wadsworth, J., et al. Polycystic ovaries – a common finding in normal women. Lancet 1:8590 (1988), 870–872.
51. 51 Dewailly, D., Lujan, M.E., Carmina, E., et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 20:3 (2014), 334–352.
52. 52 Dewailly, D., Gronier, H., Poncelet, E., et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 26:11 (2001), 3123–3129.
53. 53 Rosenfeld, R.L., Clinical review: adolescent anoluvlation: maturational mechanisms and implications. J Clin Endocrinol Metab 98:9 (2013), 3572–3583.
54. 54 Mortenson, M., Rosenfeld, R.L., Littlejohn, E., Functional significance of polycystic-size ovaries in healthy adolescents. J Clin Endocrinol Metab 91:10 (2006), 3786–3790.
55. 55 Ehrmann, D.A., Barnes, R.B., Rosenfeld, R.L., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:1 (1999), 141–146.
56. 56 Legro, R.S., Kunselman, A.R., Dodson, W.C., et al. Prevalence and predictors of risk for type 2 diabtes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:1 (1999), 165–169.
57. 57 Legro, R.S., Gnatuk, C.L., Kunselman, A.R., et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90:6 (2005), 3236–3242.
58. 58 Norman, R.J., Masters, L., Milner, C.R., et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16:9 (2001), 1995–1998.
59. 59 Boudreaux, M.Y., Talbott, E.O., Kip, K.E., et al. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow up. Curr Diab Rep 6:1 (2006), 77–83.
60. 60 Barbieri, R.L., Makris, A., Randall, R.W., et al. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 62 (1986), 904–909.
61. 61 Dunaif, A., Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997), 774–800.
62. 62 Neville, K.A., Walker, J.L., Precocious pubarche is associated with SGA, prematurity, weight gain, and obesity. Arch Dis Child 90 (2005), 258–261.
63. 63 Littlejohn, E.E., Weiss, R.E., Deplewski, D., et al. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. J Pediatr Endocrinol Metab 20 (2007), 41–51.
64. 64 McCartney, C.R., Prendergast, K.A., Blank, S.K., et al. Maturation of luteinizing hormone (gonadotropin-releasing hormone) secretion across puberty: evidence for altered regulation in obese peripubertal girls. J Clin Endocrinol Metab 94 (2009), 56–66.
65. 65 McCartney, C.R., Blank, S.K., Prendergast, K.A., et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenism in pre- and early pubertal obese girls. J Clin Endocrinol Metab 92 (2007), 430–436.
66. 66 Hart, R., Doherty, D.A., Mori, T., et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril 95:7 (2011), 2347–2353 2353.e1.
67. 67 Morrison, J.A., Glueck, C.J., Daniels, S., et al. Adolescent oligomenorrhea in a biracial schoolgirl cohort: a simple clinical parameter predicting impaired fasting glucose plus type 2 diabetes mellitus, insulin, glucose, insulin resistance, and centripetal obesity from age 19 to 25 years. Metabolism 60:9 (2011), 1285–1293.
68. 68 Keefe, C.C., Goldman, M.M., Zhang, K., et al. Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry. PLoS One, 9(4), 2014, e93805.
69. 69 Chang, W.Y., Knochenhauer, E.S., Bartolucci, A.A., et al. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 83:6 (2005), 1717–1723.
70. 70 Janse, F., Eijkemans, M.J., Goverde, A.J., et al. Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. Eur J Endocrinol 165:6 (2011), 925–933.
71. 71 Tosi, F., Fiers, T., Kaufman, J.M., et al. Implications of androgen assay accuracy in the phenotyping of women with polycystic ovarysyndrome. J Clin Endocrinol Metab 101:2 (2015), 610–618.
72. 72 Auchus, R.J., Steroid assays and endocrinology: best practices for basic scientists. Endocrinology 155:6 (2014), 2049–2051.
73. 73 Kumar, A., Woods, K.S., Bartolucci, A.A., et al. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 62:6 (2005), 644–649.
74. 74 Gambineri, A., Fanelli, F., Prontera, O., et al. Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on italian high-school students. J Clin Endocrinol Metab 98:4 (2013), 1641–1650.
75. 75 Bhide, P., Dilgil, M., Gudi, A., et al. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimüllerian hormone than its counterpart in a normal ovary: an observational cross-sectional study. Fertil Steril 103:2 (2015), 537–541.
76. 76 Dumont, A., Robin, G., Catteau-Jonard, S., et al. Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reprod Biol Endocrinol, 13(1), 2015, 137.
77. 77 Villarroel, C., Merino, P.M., López, P., et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod 26:10 (2011), 2861–2868.
78. 78 Villarroel, C., López, P., Merino, P.M., et al. Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents. Gynecol Endocrinol 31:8 (2015), 625–629.
79. 79 Pall, M., Azziz, R., Beires, J., et al. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril 94:2 (2010), 684–689.
80. 80 Deneux, C., Tardy, V., Dib, A., et al. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 86 (2001), 207–213.
81. 81 Rosencrantz, M.A., Coffler, M.S., Haggan, A., et al. Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96 (2011), 1106–1113.
82. 82 Oncul, M., Sahmay, S., Tuten, A., et al. May AMH levels distinguish LOCAH from PCOS among hirsute women?. Eur J Obstet Gynecol Reprod Biol 178:14 (2014), 182–191.
83. 83 Azziz, R., Hincapie, L.A., Knochenhauer, E.S., et al. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 72 (1999), 915–925.
84. 84 Finkielstain, G.P., Chen, W., Mehta, S.P., et al. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 96:1 (2011), E161–E172.
85. 85 Agapova, S.E., Cameo, T., Sopher, A.B., et al. Diagnosis and challenges of polycystic ovary syndrome in adolescence. Semin Reprod Med 32:3 (2014), 194–201.
86. 86 Thomson, R.L., Buckley, J.D., Noakes, M., et al. The effect of hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 93 (2008), 3373–3380.
87. 87 Florakis, D., Diamanti-Kandarakis, E., Katsikis, I., et al. Effect of hypocaloric diet plus subutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obes (Lond) 32 (2008), 692–699.
88. 88 Pasquali, R., Gambineri, A., Cavazza, C., et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 164 (2011), 53–60.
89. 89 Kiddy, D.S., Hamilton-Fairley, D., Bush, A., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 (1992), 105–111.
90. 90 Vrbíková, J., Cibula, D., Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11 (2005), 277–291.
91. 91 Pfeifer, S.M., Dayal, M., Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin North Am 30 (2003), 337–352.
92. 92 Ibáñez, L., López-Bermejo, A., Díaz, M., et al. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab 96:8 (2011), E1262–E1267.
93. 93 Gangle, M.F., Miele, L., Lanzone, A., et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 75:4 (2011), 520–527.